Whitepaper · Pharma & Life Sciences
AI in Life-Sciences Operations: Where It Helps, Where It Must Not
18 September 2026 · 8 min read
AI in life sciences operations is most useful in the document-heavy, repetitive work that surrounds research, trials, regulatory submissions and supply: assembling, reconciling, drafting and checking. It must not make the decisions that a regulator, a qualified person or a clinician owns. The right question is never "can AI do this?" but "where is it safe to let it, and how would we catch it when it is wrong?"
This guide is for operators, consultants, founders and working professionals in pharmaceuticals, biotech, medical devices, contract research and healthcare supply, in India, the UAE, Kenya and elsewhere. It maps the operational surface, sorts tasks into "help" and "must not", and sets out the guardrails regulators already expect. It is not regulatory or legal advice: for any regulated decision, follow your regulator's current guidance and involve qualified regulatory and quality professionals.
Why Life Sciences Is a Stress Test for Applied AI
Life sciences is a useful stress test because two things are true at once. Much of the work is slow, repetitive and document-heavy, exactly where AI tools save time. And the cost of a quiet error is high, because it can reach a patient, a trial result or a regulatory record, and the regulated parts are not negotiable.
Regulators have responded by publishing their thinking rather than waiting. The US Food and Drug Administration issued a draft guidance in January 2025, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. It is non-binding and proposes a risk-based credibility assessment framework for an AI model in a particular "context of use". The European Medicines Agency published its reflection paper on the use of AI in the medicinal product lifecycle in September 2024, covering every step from drug discovery to the post-authorisation setting. The World Health Organization's 2023 publication Regulatory considerations on artificial intelligence for health sets out the themes of risk-benefit assessment, evaluation and ongoing monitoring.
The common thread is that the use, not the technology, determines the risk. The same model can be harmless when it drafts a meeting summary and serious when its output feeds a safety decision.
The Operational Surface: Where the Work Actually Is
Research Operations
Literature searches, protocol drafting, lab inventory, sample tracking, equipment scheduling and the administration of grants and collaborations. Much of this is coordination work that sits outside the regulated science itself.
Clinical Trial Administration
Site feasibility, investigator correspondence, document collection, training records, query management and the tracking of essential documents. The volume is large and the format is often inconsistent.
Regulatory and Quality Paperwork
Assembling submission dossiers, maintaining standard operating procedures, managing change controls and deviations, and preparing for inspections. Accuracy and traceability matter more than speed here.
Manufacturing and Supply
Demand planning, cold-chain monitoring, batch record review support, supplier qualification files and distribution paperwork, including import and export documents.
Commercial and Medical Affairs Support
Handling routine medical information enquiries, organising scientific content and tracking approvals of promotional material through review.
Where AI in Life Sciences Helps
The safest and most valuable uses remove a handoff or a re-keying step rather than a judgement.
- Assembling documents: pulling the right sections, versions and references into a draft dossier or inspection pack for a person to review.
- Reconciling records: comparing lists such as site training logs against a delegation log, or shipments against receipts, and flagging mismatches.
- Drafting first versions: standard letters, meeting minutes, summaries of long correspondence and first drafts of procedural documents.
- Searching and summarising literature for a scientist to read and verify, with every source listed.
- Classifying incoming material: routing enquiries, documents and queries to the right team, with uncertain cases sent to a person.
- Monitoring and alerting: watching temperature logs or inventory levels and alerting a person when a threshold is crossed.
In each case the output is reviewed before it is used, the source is visible, and a mistake shows up where a person will see it.
Where Must AI in Life Sciences Not Make the Call?
- Safety judgements. Deciding whether an adverse event is serious, related to a product or reportable. AI may help organise case information; a qualified person decides.
- Batch release and quality decisions. Releasing product, closing a deviation or approving a change control remain with the responsible quality personnel.
- Clinical decisions about patients. Diagnosis and treatment belong to clinicians, and AI used for those purposes may itself be a regulated medical device.
- Trial eligibility and data integrity decisions. Whether a participant is eligible, or whether data is valid, is owned by the investigator and the sponsor.
- Regulatory statements. What is submitted to a regulator, and the claims made in it, are signed off by people who answer for them.
The line to hold is around decisions that must stay human and audited. AI can assemble a submission, reconcile records or draft a first version; it does not get to make the call that a regulator or a clinician owns.
The Guardrails Regulators Already Expect
Define the Context of Use
Write down exactly what the tool does, what its output is used for and what decision it feeds. This is the starting point of the FDA's draft credibility framework, and it is good practice even where that guidance does not apply.
Keep Audit Trails and Validated Records
Electronic records in regulated work already have rules. The FDA's guidance on Part 11, Electronic Records; Electronic Signatures recommends deciding on audit trails and the extent of validation through a documented risk assessment. An AI tool that touches regulated records needs the same thinking: who changed what, when, and on whose approval.
Maker-Checker on Every Regulated Output
The tool makes; a qualified person checks and approves. The approval, not the draft, is the regulated act. This is the same principle as in what you can, and cannot, delegate to an agent, with higher stakes.
Monitor After Launch
WHO's 2023 publication stresses evaluation and ongoing monitoring. Sample the tool's outputs on a schedule, track how often reviewers correct them, and investigate when the correction rate changes.
Control the Data
Clinical and patient data is sensitive and protected by law in every market. Know which provider processes it, where, and under what terms. In India, the UAE and Kenya, national data protection laws apply in addition to any sector rules.
How to Start: A Practical Sequence
- Map one process outside the most regulated decisions, such as trial document collection or supplier file maintenance. The method is in how to see where a business leaks time and money.
- Mark every step as "help" or "must not". Involve quality and regulatory colleagues from the start, not at the end.
- Choose one "help" step where the output is reviewed anyway, and test a tool against real documents, as in judging an AI tool against a real task.
- Write the context of use and the review step into a procedure before go-live.
- Measure before and after, including review time and corrections, using costing a process before and after AI.
- Widen slowly, one step at a time, with each extension reviewed by quality.
An Illustrative Example
This is an illustrative example, not a real case. A contract research organisation collects essential documents from dozens of trial sites: CVs, training certificates, signed delegation logs. Today, coordinators check each document by hand against a tracker. An AI-assisted process reads incoming documents, identifies the type, extracts names and dates, and flags gaps such as an expired certificate or a staff member on the delegation log without a training record. A coordinator reviews every flag and every filing before the tracker is updated. The tool never decides whether a site is ready to enrol participants; that decision stays with the study team.
Does the Market Change the Answer?
The principles travel, but the rules are local. India's medicines regulator, the UAE's health authorities and Kenya's pharmacy and poisons regulator each set their own requirements, and companies exporting to the US or Europe must also follow FDA or EMA expectations. Before any AI tool touches a regulated process, confirm the current position with qualified regulatory professionals in each market the product is sold in.
Learning to Apply AI Where It Is Safe
Separating the work AI can help with from the decisions it must not make is a core skill in the AI Entrepreneurship Programme. You can explore how it applies to pharmaceuticals and other sectors on the industries page or with Pathfinder, and see the sequence in what you learn. Participants do not have access to client work or client data.
The programme is business consulting and training. It is not a regulatory qualification, and it does not promise a job or a business outcome.
Sources
- US FDA, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (draft guidance, January 2025)
- European Medicines Agency, Reflection paper on the use of AI in the medicinal product lifecycle (2024)
- World Health Organization, Regulatory considerations on artificial intelligence for health (2023)
- US FDA, Part 11, Electronic Records; Electronic Signatures: Scope and Application
Frequently Asked Questions
Is AI allowed in regulated pharmaceutical work?
Yes, and regulators including the FDA and EMA have published their thinking on it. What matters is the use: the more directly an AI output feeds a regulated decision, the more evidence of credibility and control a regulator will expect.
What does context of use mean?
It is a precise description of what an AI model does and how its output is used in a decision. The FDA's January 2025 draft guidance builds its risk-based credibility framework around it.
Is the FDA's AI guidance binding?
The January 2025 document is a draft guidance and is described as containing non-binding recommendations. It still signals what the agency is likely to expect, so it is worth reading early.
Can AI write a regulatory submission?
It can help assemble and draft sections, but every statement must be checked and approved by qualified people who answer for it. The submission is the company's responsibility, not the tool's.
Does AI used for scheduling or inventory need validation?
It depends on whether it affects product quality, patient safety or regulated records. Many purely administrative uses fall outside regulated scope, but decide this through a documented risk assessment with your quality team.
What is the safest first use of AI in a life sciences company?
Document classification and reconciliation in administrative processes, where every output is reviewed by a person and a mistake is easy to spot and reverse.
Is AI that supports diagnosis a medical device?
Software intended for diagnosis or treatment decisions can be regulated as a medical device in many markets. Check with the relevant regulator and qualified regulatory professionals before building or deploying it.
How should patient data be handled with AI tools?
Only with a clear legal basis, a known processor, agreed terms and the minimum data needed. National data protection laws in India, the UAE and Kenya apply alongside health sector rules.
Who should own an AI project in a life sciences firm?
An operational owner for the process, with quality and regulatory colleagues involved from the start. Leaving quality review to the end usually means rework or a stalled launch.
Do the same rules apply in India, the UAE and Kenya?
No. Each market has its own medicines and health regulators. Companies selling into the US or Europe must also meet FDA or EMA expectations, so confirm requirements market by market.
Pathfinder · Free
Where Do You Fit in the AI Economy?
Type your industry and the work you do. See the live businesses you would learn inside, your twelve weeks, and three venture ideas made for you.
Find My Path
Join the Discussion
Agree, disagree or add your own experience. Every comment is reviewed before it appears; spam and abuse are removed, and disagreement is welcome.
No comments yet. Be the first to share a view.